文献速递心脑血管急症消化、代谢与肾脏急症

舍曲林对创伤性脑损伤后抑郁障碍的影响:随机对照研究的Meta分析

The influence of sertraline on depressive disorder after traumatic brain injury: A meta-analysis of randomized controlled studies.
PubMed 文献 · Am J Emerg Med · 2019-06-29
一句话结论Meta分析显示舍曲林对创伤性脑损伤后抑郁障碍无明显获益,HAM-D、焦虑、攻击性及生活质量评分与对照无显著差异。

本系统评价与Meta分析纳入5项随机对照试验,评估舍曲林治疗创伤性脑损伤后抑郁障碍的疗效。舍曲林初始使用在创伤性脑损伤后8周内。与对照组相比,舍曲林在汉密尔顿抑郁量表评分(Std. MD=-0.08;95%CI -0.45至0.28;P=0.65)、焦虑评分(Std. MD=0.08;95%CI -0.32至0.48;P=0.69)、攻击性评分(Std. MD=-0.12;95%CI -0.56至0.32;P=0.59)及生活质量评分(Std. MD=-0.06;95%CI -0.49至0.37;P=0.78)方面均无显著改善。腹泻、头晕、口干、恶心或呕吐等不良事件两组无统计学差异。结论认为舍曲林对创伤性脑损伤后抑郁障碍的缓解无明显获益。

要点

  • 5项RCT的Meta分析显示,舍曲林与对照相比未显著改善创伤性脑损伤后抑郁障碍的HAM-D评分(Std. MD=-0.08;95%CI -0.45至0.28;P=0.65)。
  • 舍曲林对焦虑评分(Std. MD=0.08;95%CI -0.32至0.48;P=0.69)、攻击性评分(Std. MD=-0.12;95%CI -0.56至0.32;P=0.59)及生活质量评分(Std. MD=-0.06;95%CI -0.49至0.37;P=0.78)均无显著改善。
  • 腹泻(RR=0.85;95%CI 0.92至3.71;P=0.08)、头晕(RR=1.15;95%CI 0.57至2.31;P=0.70)、口干(RR=2.44;95%CI 0.43至13.89;P=0.32)、恶心或呕吐(RR=1.17;95%CI 0.37至3.70;P=0.79)两组无统计学差异。
  • 舍曲林初始使用在创伤性脑损伤后8周内,但该Meta分析未显示其对抑郁障碍的缓解有明显获益。

适用人群与场景

  • 创伤性脑损伤后抑郁障碍患者,纳入的随机对照试验中舍曲林初始使用在创伤性脑损伤后8周内。

研究设计与关键结果

  • 本系统评价与Meta分析纳入5项随机对照试验,评估舍曲林治疗创伤性脑损伤后抑郁障碍的疗效,舍曲林初始使用在创伤性脑损伤后8周内。
  • 与对照组相比,舍曲林治疗在汉密尔顿抑郁量表评分上无显著改善(Std. MD=-0.08;95%CI -0.45至0.28;P=0.65)。
  • 与对照组相比,舍曲林在焦虑评分(Std. MD=0.08;95%CI -0.32至0.48;P=0.69)、攻击性评分(Std. MD=-0.12;95%CI -0.56至0.32;P=0.59)及生活质量评分(Std. MD=-0.06;95%CI -0.49至0.37;P=0.78)上均无显著改善。
  • 舍曲林组与对照组在腹泻(RR=0.85;95%CI 0.92至3.71;P=0.08)、头晕(RR=1.15;95%CI 0.57至2.31;P=0.70)、口干(RR=2.44;95%CI 0.43至13.89;P=0.32)、恶心或呕吐(RR=1.17;95%CI 0.37至3.70;P=0.79)方面无统计学差异。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析,纳入5项随机对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为舍曲林对创伤性脑损伤后抑郁障碍的缓解无明显获益。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Sertraline showed some potential in alleviating depressive disorder after traumatic brain injury. This systematic review and meta-analysis was conducted to investigate the efficacy of sertraline on the treatment of depressive disorder after traumatic brain injury.

METHODS: The databases including PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases were systematically searched for collecting the randomized controlled trials (RCTs) regarding the efficacy of sertraline for traumatic brain injury.

RESULTS: This meta-analysis included five RCTs. The initial use of sertraline was within 8 weeks after traumatic brain injury. Compared with control group for traumatic brain injury, sertraline treatment showed no significant improvement on Hamilton Depression Rating Scale (HAM-D) (standard mean difference (Std. MD) = -0.08; 95% confidence interval (CI) = -0.45 to 0.28; P = 0.65), anxiety score (Std. MD = 0.08; 95% CI = -0.32 to 0.48; P = 0.69), aggression score (Std. MD = -0.12; 95% CI = -0.56 to 0.32; P = 0.59), or quality of life (QOL) score (Std. MD = -0.06; 95% CI = -0.49 to 0.37; P = 0.78). There was no statistical difference of diarrhea (risk ratio (RR) = 0.85; 95% CI = 0.92 to 3.71; P = 0.08), dizziness (RR = 1.15; 95% CI = 0.57 to 2.31; P = 0.70), dry mouth (RR = 2.44; 95% CI = 0.43 to 13.89; P = 0.32), nausea or vomiting (RR = 1.17; 95% CI = 0.37 to 3.70; P = 0.79) between sertraline group and control group.

CONCLUSIONS: Sertraline showed no obvious benefits for the relief of depressive disorder after traumatic brain injury.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Gao C, Fu Q, Chen P, et al. The influence of sertraline on depressive disorder after traumatic brain injury: A meta-analysis of randomized controlled studies. Am J Emerg Med. 2019. PMID: 31326198. doi:10.1016/j.ajem.2019.06.050

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。